Clinical Trials Browser

Withdrawn × Biological Therapy × Clear all

NCT00101140 2017-10-19

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Phase 2 Withdrawn

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00072540 2013-11-08

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Phase 2 Withdrawn

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00003455 2013-07-10

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00003486 2013-07-10

Antineoplaston Therapy in Treating Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms

NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Phase 2 Withdrawn

Lymphoma, Mantle-Cell

NCT00003517 2013-07-10

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

Phase 2 Withdrawn

Carcinoma, Basal Cell